HAS says OK to continue the reimbursement of Zykadia (ceritinib) for ALK + NSCLC
HAS gave a positive opinion to continue the reimbursement of Zykadia (ceritinib) for patients with ALK-positive non-small-cell lung cancer. The drug is reimbursed for patients who were previously treated with crizotinib.
Crizotinib is the first product approved for ALK-positive NSCLC, which demonstrated the superiority over chemotherapy.
Alecensa (alectinib) had demonstrated superiority in progression-free survival and the risk of brain progression over crizotinib; it is the preferred treatment option for the first-line treatment of ALK+ lung cancer.
HAS has recommended Zyadia as a second-line treatment option after failure of first treatment (preferentially alectinib).
Zyadia received ASMR V considering the gain in progression-free survival versus chemotherapy. However, HAS believed that the trial result does not reflect the current treatment strategy.
The product has achieved SMR ‘Important.’